INDEGENE Financial Statement Analysis
|
||
|
The Revenues of INDEGENE have increased by 9.64% YoY .
The Earnings Per Share (EPS) of INDEGENE has increased by 11.93 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
INDEGENE Last 5 Annual Financial Results
[BOM: 544172|NSE : INDGN]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹2,839 Cr | ₹2,590 Cr | ₹2,306 Cr | ₹1,665 Cr | ₹966 Cr |
| Expenses | ₹2,305 Cr | ₹2,084 Cr | ₹1,910 Cr | ₹1,378 Cr | ₹736 Cr |
| Operating Profit (Excl OI) | ₹534 Cr | ₹505 Cr | ₹396 Cr | ₹287 Cr | ₹231 Cr |
| Other Income | ₹107 Cr | ₹76 Cr | ₹58 Cr | ₹26 Cr | ₹31 Cr |
| Interest | ₹22 Cr | ₹49 Cr | ₹31 Cr | ₹5.96 Cr | ₹6.96 Cr |
| Depreciation | ₹80 Cr | ₹76 Cr | ₹60 Cr | ₹33 Cr | ₹26 Cr |
| Profit Before Tax | ₹539 Cr | ₹459 Cr | ₹363 Cr | ₹226 Cr | ₹231 Cr |
| Profit After Tax | ₹407 Cr | ₹337 Cr | ₹266 Cr | ₹163 Cr | ₹186 Cr |
| Consolidated Net Profit | ₹407 Cr | ₹337 Cr | ₹266 Cr | ₹165 Cr | ₹149 Cr |
| Earnings Per Share (Rs) | ₹16.98 | ₹15.17 | ₹12.01 | ₹938.81 | ₹954.66 |
| PAT Margin (%) | 14.32 | 13.00 | 11.54 | 9.78 | 19.22 |
| ROE(%) | 20.45 | 27.56 | 29.50 | 30.20 | 176.32 |
| ROCE(%) | 25.24 | 30.88 | 35.20 | 41.09 | 68.54 |
| Total Debt/Equity(x) | 0.00 | 0.29 | 0.38 | 0.02 | 0.08 |
Key Financials |
||
| Market Cap | : | ₹ 13,550.0 Cr |
| Revenue (TTM) | : | ₹ 2,839.3 Cr |
| Net Profit(TTM) | : | ₹ 406.7 Cr |
| EPS (TTM) | : | ₹ 16.9 |
| P/E (TTM) | : | 33.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDEGENE | -0.7% | -5.7% | 1.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | -0.9% | 4.8% |
| DIVIS LABORATORIES | -0.7% | 1.6% | 50.2% |
| CIPLA | -1.7% | -1.1% | -2.3% |
| TORRENT PHARMACEUTICALS | -1.1% | 1.6% | 13.7% |
| DR REDDYS LABORATORIES | -4.3% | -8% | -4.4% |
| MANKIND PHARMA | 6.8% | 8% | 20.9% |
| ZYDUS LIFESCIENCES | -1.9% | 0.1% | -16.5% |
| LUPIN | -4.3% | -6.4% | 4.6% |
INDEGENE Revenues
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 9.64 % |
| 5 Yr CAGR | 30.93 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹2,839 Cr | 9.64 | |
| Mar2024 | ₹2,590 Cr | 12.29 | |
| Mar2023 | ₹2,306 Cr | 38.54 | |
| Mar2022 | ₹1,665 Cr | 72.27 | |
| Mar2021 | ₹966 Cr | - | |
INDEGENE Operating Profit
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 5.72 % |
| 5 Yr CAGR | 23.39 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹534 Cr | 5.72 | |
| Mar2024 | ₹505 Cr | 27.66 | |
| Mar2023 | ₹396 Cr | 37.98 | |
| Mar2022 | ₹287 Cr | 24.46 | |
| Mar2021 | ₹231 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -3.59 % |
| 5 Yr CAGR | -5.76 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 18.82% | -3.59 | |
| Mar2024 | 19.52% | 13.69 | |
| Mar2023 | 17.17% | -0.41 | |
| Mar2022 | 17.24% | -27.75 | |
| Mar2021 | 23.86% | - | |
INDEGENE Profit After Tax
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 20.79 % |
| 5 Yr CAGR | 28.45 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹407 Cr | 20.79 | |
| Mar2024 | ₹337 Cr | 26.53 | |
| Mar2023 | ₹266 Cr | 61.51 | |
| Mar2022 | ₹165 Cr | 10.28 | |
| Mar2021 | ₹149 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 10.15 % |
| 5 Yr CAGR | -7.09 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 14.32 % | 10.15 | |
| Mar2024 | 13 % | 12.65 | |
| Mar2023 | 11.54 % | 18.00 | |
| Mar2022 | 9.78 % | -49.12 | |
| Mar2021 | 19.22 % | - | |
INDEGENE Earnings Per Share (EPS)
[BOM: 544172|NSE : INDGN]
| Y-o-Y | 11.93 % |
| 5 Yr CAGR | -63.48 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹17 | 11.93 | |
| Mar2024 | ₹15 | 26.31 | |
| Mar2023 | ₹12 | -98.72 | |
| Mar2022 | ₹939 | -1.66 | |
| Mar2021 | ₹955 | - | |
INDEGENE Return on Capital Employed (ROCE)
[BOM: 544172|NSE : INDGN]
| Y-o-Y | -18.26 % |
| 5 Yr CAGR | -22.10 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 25.24% | -18.26 | |
| Mar2024 | 30.88% | -12.27 | |
| Mar2023 | 35.2% | -14.33 | |
| Mar2022 | 41.09% | -40.05 | |
| Mar2021 | 68.54% | - | |
INDEGENE Share Price vs Sensex
| Current Share Price | : | ₹564.4 |
| Current MarketCap | : | ₹ 13,550.0 Cr |
| Updated EOD on | : | Jul 11,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | -0.7% |
-5.7% |
1.7% |
| SENSEX | -1.1% |
-0% |
3.2% |
INDEGENE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE SELECT IPO INDEX | 0.1% | 0.2% | NA |
| BSE SMALLCAP | -0.6% | 0.4% | 0.8% |
| BSE HEALTHCARE | -1.3% | 0.7% | 16.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY IPO INDEX | 1.4% | 2% | NA |
| NIFTY SMALLCAP 250 | -0.7% | 0.7% | -0.1% |
| NIFTY 500 EQUAL WEIGHT | -0.7% | -0.3% | -0.3% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -1.1% | -0.2% | 1.2% |
| NIFTY500 MULTICAP 50:25:25 | -1.1% | -0.2% | 1.3% |
You may also like the below Video Courses
FAQ about INDEGENE Financials
How the annual revenues of INDEGENE have changed ?
The Revenues of INDEGENE have increased by 9.64% YoY .
How the Earnings per Share (EPS) of INDEGENE have changed?
The Earnings Per Share (EPS) of INDEGENE has increased by 11.93 % YoY .
Check out Intrinsic Value of Peers of INDEGENE
Compare Stock Analytics of Peers of INDEGENE
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
